Cargando…

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

BACKGROUND: Immune checkpoint inhibitors have revolutionized the treatment paradigm of highly lethal malignancies like advanced non-small cell lung cancer (NSCLC), demonstrating long-term tumour control and extended patient survival. Unfortunately, only 25–30% of patients experience a durable benefi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Botticelli, Andrea, Cerbelli, Bruna, Lionetto, Luana, Zizzari, Ilaria, Salati, Massimiliano, Pisano, Annalinda, Federica, Mazzuca, Simmaco, Maurizio, Nuti, Marianna, Marchetti, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080500/ https://www.ncbi.nlm.nih.gov/pubmed/30081936 http://dx.doi.org/10.1186/s12967-018-1595-3

Ejemplares similares

Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
por: Botticelli, Andrea, et al.
Publicado: (2020)

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
por: Botticelli, Andrea, et al.
Publicado: (2019)

Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer
por: Borro, Marina, et al.
Publicado: (2016)

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
por: Botticelli, Andrea, et al.
Publicado: (2016)

Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?
por: Botticelli, Andrea, et al.
Publicado: (2016)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
por: Botticelli, Andrea, et al.
Publicado: (2021)

Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort
por: Mazzuca, Federica, et al.
Publicado: (2016)

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
por: Botticelli, Andrea, et al.
Publicado: (2020)

Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study
por: Rossi, Ernesto, et al.
Publicado: (2022)

IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137(+)T-cells
por: Ugolini, Alessio, et al.
Publicado: (2020)

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
por: Botticelli, Andrea, et al.
Publicado: (2017)

PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
por: Cerbelli, Bruna, et al.
Publicado: (2017)

Fatigue in Patients on Chronic Hemodialysis: The Role of Indoleamine 2,3-Dioxygenase (IDO) Activity, Interleukin-6, and Muscularity
por: Molfino, Alessio, et al.
Publicado: (2023)

The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
por: Botticelli, Andrea, et al.
Publicado: (2021)

Circulating CD137(+) T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients
por: Cirillo, Alessio, et al.
Publicado: (2023)

Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2020)

Combination Therapy of High-Dose Rabeprazole Plus Metronomic Capecitabine in Advanced Gastro-Intestinal Cancer: A Randomized Phase II Trial
por: Roberto, Michela, et al.
Publicado: (2020)

Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis
por: Cerbelli, Bruna, et al.
Publicado: (2022)

Effect of MTHFR Polymorphisms on Gastrointestinal Cancer Risk in Italy
por: Mazzuca, Federica, et al.
Publicado: (2015)

Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis
por: Scirocchi, Fabio, et al.
Publicado: (2022)

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
por: Della Corte, Carminia Maria, et al.
Publicado: (2022)

Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined Profile
por: Mezi, Silvia, et al.
Publicado: (2022)

FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?
por: Botticelli, Andrea, et al.
Publicado: (2015)

The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial
por: Botticelli, Andrea, et al.
Publicado: (2020)

Integrated OMICS tools for personalised medicine
por: Borro, Marina, et al.
Publicado: (2015)

The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy
por: Botticelli, Andrea, et al.
Publicado: (2022)

Circulating CD137(+) T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2022)

Immune effects of CDK4/6 inhibitors in patients with HR(+)/HER2(−) metastatic breast cancer: Relief from immunosuppression is associated with clinical response
por: Scirocchi, Fabio, et al.
Publicado: (2022)

Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2020)

A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors
por: Mezi, Silvia, et al.
Publicado: (2023)

Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN(®) System Comprehensive Approach
por: Roberto, Michela, et al.
Publicado: (2021)

Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-Type Lectin (MGL)
por: Napoletano, Chiara, et al.
Publicado: (2020)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

IDO1 Promotes the Progression of NSCLC by Regulating the Polarization of M2 Macrophages
por: Chen, Xiao, et al.
Publicado: (2023)

Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
por: Mezi, Silvia, et al.
Publicado: (2021)

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy
por: Botticelli, Andrea, et al.
Publicado: (2020)

The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
por: Roberto, Michela, et al.
Publicado: (2021)

Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines
por: Mazzuca, Federica, et al.
Publicado: (2018)

Validation of a small-size pooling approach targeting hospital surveillance of SARS-CoV-2 infection
por: Petrucca, Andrea, et al.
Publicado: (2020)

MGL Receptor and Immunity: When the Ligand Can Make the Difference
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ifk1kt6s12frnlrqeat13p4u2a